Biodexa Pharmaceuticals (BDRX) Liabilities and Shareholders Equity (2013 - 2025)

Biodexa Pharmaceuticals has reported Liabilities and Shareholders Equity for 13 years, with the latest figure at $24.2 million in Q4 2025.

• Quarterly Liabilities and Shareholders Equity rose 27.47% year-over-year to $24.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $80.6 million (up 35.05% YoY) and the FY2025 annual result came in at $24.0 million, up 26.35% from the prior year.
• Liabilities and Shareholders Equity improved to $24.2 million in Q4 2025 per BDRX's latest filing, from $19.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $24.2 million in Q4 2025 and troughed at $6.5 million in Q4 2022.
• A 5-year average of $15.1 million and a median of $15.2 million in 2021 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity slumped 62.77% in 2022, then soared 101.9% in 2023.
• Over 5 years, Liabilities and Shareholders Equity stood at $17.4 million in 2021, then plunged by 62.77% to $6.5 million in 2022, then soared by 101.9% to $13.1 million in 2023, then soared by 44.98% to $19.0 million in 2024, then climbed by 27.47% to $24.2 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $24.2 million, $19.8 million, and $19.0 million for Q4 2025, Q2 2025, and Q4 2024 respectively.